HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

glucuronyl glucosamine glycan sulfate (Vessel)

Also Known As:
Vessel; sulodexide; Luzone; 3-glucosaminoglycan sulfate; Aterina; Sigma-Tau brand of glucuronyl glucosamine glycan sulfate; Tedec Meiji brand of glucuronyl glucosamine glycan sulfate; Vessel (polysaccharide); glucuronyl glucosaminoglycan sulfate; glucuronylglucosaminoglycan sulfate
Networked: 33718 relevant articles (948 outcomes, 2329 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Serruys, Patrick W: 140 articles (12/2015 - 02/2002)
2. Stone, Gregg W: 135 articles (01/2016 - 01/2002)
3. Mehran, Roxana: 87 articles (01/2016 - 01/2002)
4. Colombo, Antonio: 69 articles (12/2015 - 02/2002)
5. Waksman, Ron: 64 articles (12/2015 - 01/2002)
6. Windecker, Stephan: 59 articles (10/2015 - 05/2002)
7. Xu, Bo: 58 articles (12/2015 - 09/2005)
8. Lansky, Alexandra J: 57 articles (07/2015 - 01/2002)
9. Dichgans, Martin: 56 articles (08/2015 - 01/2002)
10. Park, Seung-Jung: 54 articles (10/2015 - 04/2003)

Related Diseases

1. Neoplasms (Cancer)
2. Pathologic Constriction (Stenosis)
3. Thrombosis (Thrombus)
4. Stroke (Strokes)
5. Myocardial Infarction
06/01/2012 - "Excellent target vessel recanalization (Thrombolysis in Myocardial Infarction score of 3) and good outcome at 90 days (modified Rankin Score ≤ 2) were more common in younger patients (45% versus 14%, P = .047, and 41% versus 0%, P = .008, respectively). "
05/01/2009 - "All the treated vessels (100%) were successfully re-canalized, Trials In Myocardial Infarction (TIMI) score of 3. At 90-day follow-up, of the 5 patients treated, 2 had modified Rankin score (mRS) of < 2. This small series shows the safety and efficacy of the Penumbra System in the thrombolysis of large vessel occlusive disease."
05/01/1993 - "Different thrombolytic regimens for acute myocardial infarction proved to be equally effective in large scale mortality trials despite significant differences in their efficacy with respect to early infarct-related vessel patency as shown in smaller angiographic trials. "
12/01/2010 - "In this patient-level pooled analysis, EES compared with PES resulted in a significant and persistent reduction in target vessel failure and major adverse cardiac events at 3 years due to fewer myocardial infarction and ischemic target lesion revascularization events, which is consistent with superior safety and efficacy of the EES platform."
12/01/2009 - "The use of Endeavor versus Driver was associated with a significant reduction in target vessel revascularization through 4-year follow-up with no difference in death, nonfatal myocardial infarction, quality-adjusted survival, or total medical costs. "

Related Drugs and Biologics

1. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2. Heparin (Liquaemin)
3. Antineutrophil Cytoplasmic Antibodies (ANCA)
4. bevacizumab
5. Phenobarbital (Luminal)
6. Sirolimus (Rapamycin)
7. Oxygen
8. Cholesterol
9. Carbon Monoxide
10. Calcium

Related Therapies and Procedures

1. Stents
2. Angioplasty (Angioplasty, Transluminal)
3. Transplants (Transplant)
4. Thrombectomy
5. Catheters